Nafazatrom

**Semantic type:** Organic Chemical|Pharmacologic Substance

**Definition:** A pyrazolinone derivative with potential antimetastatic activities. Nafazatrom, originally developed as an antithrombotic agent, inhibits the key prostaglandin catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase, which prolongs the biological half-life of prostacyclin (prostaglandin I2; PGI2) and prevents intravascular coagulation. This agent also serves as a reducing cofactor with the hydroperoxidase moiety of cyclooxygenase and accelerates the conversion of arachidonic acid into precursors of PGI2. An elevated level of PGI2 prevents aggregation of platelets; subsequently it decreases the formation of tumor cell-platelet aggregates as well as their sequestration in blood vessels, which is an important initiating step in the development of metastasis.

**Synonyms:** - 1-(2-(beta-naphthyloxy)ethyl)-3-methyl-2-pyrazolin-5-one - 3H-pyrazol-3-one,2,4-dihydro-5-methyl-2-(2-(2-naphthalenyloxy)ethyl) - Bay g 6575 - Bay-g 6575 - NAFAZATROM